Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
<h4>Objective</h4>We aimed to investigate the cost-effectiveness of tislelizumab plus chemotherapy compared to chemotherapy alone as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (OSCC).<h4>Methods</h4>A partitioned survival model was d...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302961&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555366564855808 |
|---|---|
| author | Chaoneng He Xiufang Mi Gaoqi Xu Xinglu Xu Wenxiu Xin Like Zhong Junfeng Zhu Qi Shu Luo Fang Haiying Ding |
| author_facet | Chaoneng He Xiufang Mi Gaoqi Xu Xinglu Xu Wenxiu Xin Like Zhong Junfeng Zhu Qi Shu Luo Fang Haiying Ding |
| author_sort | Chaoneng He |
| collection | DOAJ |
| description | <h4>Objective</h4>We aimed to investigate the cost-effectiveness of tislelizumab plus chemotherapy compared to chemotherapy alone as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (OSCC).<h4>Methods</h4>A partitioned survival model was developed to evaluate the cost-effectiveness of tislelizumab plus chemotherapy versus chemotherapy alone in patients with advanced or metastatic OSCC over a 10-year lifetime horizon from the perspective of the Chinese healthcare system. Costs and utilities were derived from the drug procurement platform and published literature. The model outcomes comprised of costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were conducted to address uncertainty and ensure the robustness of the model.<h4>Results</h4>Tislelizumab plus chemotherapy yielded an additional 0.337 QALYs and incremental costs of $7,117.007 compared with placebo plus chemotherapy, generating an ICER of $21,116.75 per QALY, which was between 1 time ($12,674.89/QALY) and 3 times GDP ($38,024.67/QALY) per capita. In one-way sensitivity analysis, the ICER is most affected by the cost of oxaliplatin, paclitaxel and tislelizumab. In the probabilistic sensitivity analysis, when the willingness-to-pay threshold was set as 1 or 3 times GDP per capita, the probability of tislelizumab plus chemotherapy being cost-effective was 1% and 100%, respectively.<h4>Conclusion</h4>Tislelizumab plus chemotherapy was probably cost-effective compared with chemotherapy alone as the first-line treatment for advanced or metastatic OSCC in China. |
| format | Article |
| id | doaj-art-191a684b85944067aa52da6cd4ea6d52 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-191a684b85944067aa52da6cd4ea6d522025-01-08T05:33:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01195e030296110.1371/journal.pone.0302961Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.Chaoneng HeXiufang MiGaoqi XuXinglu XuWenxiu XinLike ZhongJunfeng ZhuQi ShuLuo FangHaiying Ding<h4>Objective</h4>We aimed to investigate the cost-effectiveness of tislelizumab plus chemotherapy compared to chemotherapy alone as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (OSCC).<h4>Methods</h4>A partitioned survival model was developed to evaluate the cost-effectiveness of tislelizumab plus chemotherapy versus chemotherapy alone in patients with advanced or metastatic OSCC over a 10-year lifetime horizon from the perspective of the Chinese healthcare system. Costs and utilities were derived from the drug procurement platform and published literature. The model outcomes comprised of costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were conducted to address uncertainty and ensure the robustness of the model.<h4>Results</h4>Tislelizumab plus chemotherapy yielded an additional 0.337 QALYs and incremental costs of $7,117.007 compared with placebo plus chemotherapy, generating an ICER of $21,116.75 per QALY, which was between 1 time ($12,674.89/QALY) and 3 times GDP ($38,024.67/QALY) per capita. In one-way sensitivity analysis, the ICER is most affected by the cost of oxaliplatin, paclitaxel and tislelizumab. In the probabilistic sensitivity analysis, when the willingness-to-pay threshold was set as 1 or 3 times GDP per capita, the probability of tislelizumab plus chemotherapy being cost-effective was 1% and 100%, respectively.<h4>Conclusion</h4>Tislelizumab plus chemotherapy was probably cost-effective compared with chemotherapy alone as the first-line treatment for advanced or metastatic OSCC in China.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302961&type=printable |
| spellingShingle | Chaoneng He Xiufang Mi Gaoqi Xu Xinglu Xu Wenxiu Xin Like Zhong Junfeng Zhu Qi Shu Luo Fang Haiying Ding Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. PLoS ONE |
| title | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
| title_full | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
| title_fullStr | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
| title_full_unstemmed | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
| title_short | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
| title_sort | cost effectiveness analysis of tislelizumab plus chemotherapy as the first line treatment for advanced or metastatic oesophageal squamous cell carcinoma in china |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302961&type=printable |
| work_keys_str_mv | AT chaonenghe costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT xiufangmi costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT gaoqixu costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT xingluxu costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT wenxiuxin costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT likezhong costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT junfengzhu costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT qishu costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT luofang costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina AT haiyingding costeffectivenessanalysisoftislelizumabpluschemotherapyasthefirstlinetreatmentforadvancedormetastaticoesophagealsquamouscellcarcinomainchina |